Vir(US:VIR) ZACKS·2025-02-26 23:45Group 1 - Vir Biotechnology reported a quarterly loss of $0.76 per share, better than the Zacks Consensus Estimate of a loss of $0.85, and an improvement from a loss of $0.86 per share a year ago, resulting in an earnings surprise of 10.59% [1] - The company posted revenues of $12.37 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 15.22%, and down from $16.79 million in the same quarter last year [2] - Over the last four quarters, Vir Biotechnology has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Group 2 - The stock has gained approximately 24% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.3% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the upcoming quarter is -$0.92 on revenues of $21.56 million, and for the current fiscal year, it is -$3.55 on revenues of $59.08 million [7] Group 3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 24% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Vir Biotechnology is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]